Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Regeneron Pharmaceuticals (REGN) stock fell 1.37% to $797.00 on Tuesday, underperforming competitors like Amgen, Moderna, and Gilead Sciences during a broader market decline. The drop ended a five-day winning streak, leaving the stock 2.94% below its 52-week high of $821.11. Trading volume was significantly lower than the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Regeneron Pharmaceuticals Inc. (REGN) slipped 1.37% to $797.00 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.32% to 7,728.20 and Dow Jones Industrial Average falling 0.34% to 53,791.85.
The stock's fall snapped a five-day winning streak.
Regeneron Pharmaceuticals Inc. closed 2.94% below its 52-week high of $821.11, which the company achieved on January 9th.
The stock underperformed when compared to some of its competitors Tuesday, as Amgen Inc. (AMGN) fell 0.70% to $414.30, Moderna Inc. (MRNA) rose 1.27% to $60.57, and Gilead Sciences Inc. (GILD) rose 2.04% to $135.77.
Trading volume (611,040) remained 351,006 below its 50-day average volume of 962,046.
Data source: Dow Jones Market Data, FactSet. Data compiled August 11, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-11-26 1644ET